Latest News
Allergy Therapeutics reports positive biomarker data from PROTECT trial
4 March 2026 - Biotechnology company Allergy Therapeutics plc (AIM: AGY) on Wednesday reported positive biomarker results from its Phase I/IIa PROTECT trial of VLP Peanut, following the achievement of the study's primary safety endpoint.The tria...
HUTCHMED doses first patient in global trial of ATTC candidate HMPL-A580
4 March 2026 - Biopharmaceutical company HUTCHMED (China) Limited (Nasdaq: HCM) (AIM: HCM) (HKEX: 13) announced on Wednesday that it has initiated a global Phase I/IIa clinical trial of its antibody-targeted therapy conjugate candidate HMPL-A580, wit...
Ensorcell adds new senior leadership team members
4 March 2026 - Ensorcell (ensorcell.bio), a US-based company focused on reimaging life science tools and solutions for the biopharmaceutical industry, announced on Tuesday the appointments of Geoff Hodge and Amy Teachout to its senior leadership team...
Sino Biological launches 2026-2027 Northern Hemisphere influenza vaccine strain antigens
4 March 2026 - Chinese biotechnology company Sino Biological Inc (SZ:301047) announced on Wednesday that it has launched the 2026-2027 Northern Hemisphere influenza vaccine strain antigens to accelerate vaccine development.This follows the World Heal...
Sanaregen receives FDA clearance for retinal degeneration clinical trial
3 March 2026 - Sanaregen Vision Therapeutics, a clinical-stage regenerative medicine company, on Tuesday announced US Food and Drug Administration (FDA) clearance to begin a Phase I/II clinical trial of SVT-001, its investigational cell therapy.The t...